SFPQ subcellular mislocalisation entails altered cancer cell function

Libang Yang, Adam Gilbertsen, Blake A. Jacobson, Robert A. Kratzke, Yingming Li, Bo Sun, Sabine Karam, Scott M. Dehm, Craig A. HenkeClinical 2025 · DOI

TL;DR

This study reveals that the splicing factor SFPQ, typically found in the nucleus, is aberrantly localized to the cell surface in various cancer cells. This mislocalization is linked to altered cancer cell functions like proliferation and invasion, and targeting cell surface SFPQ with antibodies shows therapeutic potential.

What Problem Does This Paper Address?

The paper addresses the phenomenon of subcellular mislocalization of proteins in cancer, a known driver of malignancy, metastasis, and drug resistance. Specifically, it investigates the splicing factor SFPQ (Splicing Factor Proline and Glutamine Rich), which is normally a nuclear protein. The researchers aim to understand if SFPQ mislocalizes in cancer cells, where it goes, and crucially, how this mislocalization impacts cancer cell behavior and if it can be exploited as a therapeutic target. The existing knowledge gap is the functional consequence of SFPQ's presence outside its canonical nuclear location, particularly on the cell surface.

Methods

The study employed a multi-pronged approach:

  • Immunohistochemistry (IHC): Used to visualize SFPQ protein distribution in normal and cancerous human tissue samples, quantifying staining intensity in different cellular compartments.
  • Subcellular Fractionation and Western Blotting: Cancer and normal cell lines were fractionated into nuclear, cytoplasmic, and membrane components. Western blotting was then used to detect and quantify SFPQ levels in each fraction, confirming its presence in non-nuclear compartments of cancer cells.
  • Immunofluorescence (IF) Staining: Employed to visualize SFPQ localization within individual cells, particularly focusing on the cell membrane.
  • Internalization Assays: Used pHrodo-labeled antibodies to track the uptake of SFPQ-binding antibodies into cancer cells, providing evidence for SFPQ's cell surface presence.
  • Flow Cytometry: Utilized to confirm SFPQ's presence on the cell surface.
  • Antibody Screening and Functional Assays: A panel of antibodies targeting cell surface SFPQ was screened. These antibodies were then used to assess their impact on cancer cell proliferation (using Ki67 as a marker), apoptosis, and invasion in vitro.
  • In Vivo Xenograft Models: Lung cancer cells were implanted into immunocompromised mice (NSG mice), and the effect of anti-SFPQ antibody treatment on tumor growth was evaluated.
  • Immunoprecipitation (IP) and Proteomics: SFPQ was immunoprecipitated from cancer cell membrane fractions to identify interacting proteins. This was followed by Ingenuity Pathway Analysis (IPA) to understand the functional implications of these interactions.
  • Knockdown Studies (shRNA): SFPQ and its interacting protein S100A4 were knocked down using shRNA to assess their roles in cell invasion and migration.

Datasets

Not explicitly detailed as distinct datasets for training/evaluation in the context of machine learning. The study utilized:

  • Human Cancer Tissue Samples: For immunohistochemistry.
  • Cancer Cell Lines: A variety of lung, prostate, kidney, liver, and breast cancer cell lines were used for in vitro experiments (e.g., H661, A549, H648, H856, RWPE-1, LNCaP, Du145, MCF, MDA468, MHCC97, HepG2, Caki-1).
  • Normal Cell Lines: Used as controls (e.g., PCS-201-020, HEK293, HBEC3-KT).
  • Immunocompromised Mice (NSG): Used for in vivo xenograft studies.

Key Insights and Ideas

  • SFPQ's Unexpected Surface Presence: The most striking finding is that SFPQ, a well-established nuclear splicing factor, is significantly present on the surface of various cancer cells. This challenges the traditional understanding of SFPQ's cellular localization and function.
  • Surface SFPQ Drives Cancer Hallmarks: The presence of SFPQ on the cell surface is not merely an artifact; it actively contributes to key cancer behaviors like proliferation and invasion. This suggests a dual role for SFPQ in cancer: nuclear roles in splicing and extracellular roles in signaling.
  • Targeting Surface SFPQ is Therapeutically Viable: The development of antibodies that bind to cell surface SFPQ and subsequently inhibit cancer cell proliferation and invasion, both in vitro and in vivo, strongly supports its potential as a therapeutic target.
  • SFPQ Interacts with Key Cancer Proteins: Proteomic analysis revealed that cell surface SFPQ interacts with proteins like S100A4, PPIA, and H2AX. The interaction with S100A4, in particular, appears crucial for cell invasion and migration.
  • SFPQ/S100A4 Complex in Invasion: The study highlights the formation of an SFPQ/S100A4 complex on the cell membrane, which directly impacts cancer cell invasion and migration, suggesting a coordinated mechanism for metastasis.

Key Results

  • Increased SFPQ Staining: Cancer tissues showed significantly higher SFPQ staining in both cytoplasmic (3.8-8.6 times greater) and nuclear (3.6-5.6 times greater) regions compared to normal tissues.
  • Membrane Localization in Cancer: SFPQ was detected in cell membrane fractions of cancer cells but not in normal cell lines.
  • Antibody Efficacy: 9 out of 19 tested antibodies targeting cell surface SFPQ showed positive binding.
  • Inhibition of Cancer Cell Functions: Anti-SFPQ antibodies inhibited cell proliferation (indicated by reduced Ki67 expression), altered apoptosis, and reduced cell invasion in vitro.
  • In Vivo Tumor Growth Attenuation: Treatment with an anti-SFPQ antibody (1A6) significantly reduced tumor growth in mice bearing lung cancer xenografts compared to control IgG treatment.
  • Interaction with S100A4: SFPQ was shown to interact with S100A4 in the cell membrane, and knockdown of either SFPQ or S100A4 inhibited cell invasion and MMP2 expression.

Limitations and Future Work

  • Specificity of Antibodies: While several antibodies showed efficacy, the paper notes that different SFPQ antibodies affect cancer cells differently, implying a need for further characterization of antibody specificity and downstream effects.
  • Mechanism of Surface Localization: The paper doesn't fully elucidate the precise mechanism by which SFPQ is trafficked to the cell surface. Future work could explore the cellular machinery involved in this mislocalization.
  • Broader Cancer Type Investigation: While SFPQ/S100A4 complex formation was observed in other solid cancer cell lines, a more extensive investigation across diverse cancer types would be beneficial.
  • Therapeutic Optimization: Further research is needed to optimize anti-SFPQ antibody-based therapies, including determining optimal dosing, delivery methods, and potential combination therapies.
  • Role of Other Interacting Proteins: The study identified other SFPQ-interacting proteins (PPIA, H2AX, VIM). Future work could delve deeper into the functional roles of these interactions in the context of cell surface SFPQ.

Summary updated

Abstract

Dear Editor, This study demonstrates that splicing factor proline and glutamine rich (SFPQ) is present on the cell surface in cancer cells, where it interacts with S100A4 and so forth proteins to alter cell function when SFPQ is a nuclear protein normally. Protein subcellular mislocalisation can alter cell function in cancer development, metastasis or drug resistance and may serve as a therapy target.1 Overexpression of SFPQ is essential for the malignancy of cancer cells.2-4 While SFPQ normally resides in the nucleus, it can be found in other subcellular locations in lung cancer cells.5 We further explore if SFPQ appears on the cell surface and its influence on cancer cells. SFPQ is more highly stained in the cancer nucleus and cytoplasmic region than the adjacent normal area in immunohistochemistry (IHC) stain in multiple cancer tissues (Figure 1A‒J). The cytoplasmic staining was 3.8‒8.6 times greater than that of the control region and nuclear staining was also more prominent (3.6‒5.6 times more than the control regions in stain density quantification analysis; Figure 1B,D,F,H,I). SFPQ is present outside of the cell nucleus in solid cancers in most cases but not in control tissues. To observe the SFPQ distribution in subcellular organelles, the cell membrane, cytoplasm and nucleus were isolated and used in a Western blot to observe the SFPQ level. With subcellular fractions from normal and cancer cell lines, we found that SFPQ was present in all of the cell membranes, cytoplasm and nuclear fractions from cancer cells but only in nuclear fractions from non-cancer cell lines (Figure 1K‒M). We then used immunofluorescence staining to determine whether SFPQ is present on the cell surface of solid cancer cell lines. We fixed the cells with paraformaldehyde (which fixes the cells but does not penetrate the cell membrane) and stained them with an SFPQ antibody. Most of the cancer cells were positive for SFPQ, which suggested that SFPQ was present on the cell surface (Figure 1N). Internalisation assay with pHrodo-labelled SFPQ antibody and lung cancer cell H661 was positive, suggesting SFPQ is a cell surface protein6 (Figure 1O). Additionally, we found SFPQ and the cell surface marker cadherin E overlapped well in immunofluorescence (IF) stain with lung cancer cells and IHC stain in lung cancer patient tissue (Figure S1) and flow cytometry result suggests that SFPQ is on the cell surface (Figure S1C). This shows SFPQ presence on the cancer cell surface. We then examine if interacting cell surface SFPQ affects cancer cell function. High SFPQ expressing lung cancer cells H661 (Figure 2A) were used to identify cell surface SFPQ binding antibodies, and 9/19 antibodies tested positive in IF stain (Figure 2B shows examples of them). Binding SFPQ could inhibit cell proliferation in lung cancer lines (Figure 2C) and other cancer cell lines from other cell types (Figure 2D). The cell proliferation marker ki67 expression levels are low in those proliferation-inhibited cells (Figure 2E). The inhibition levels are consistent with the SFPQ membrane level (Figure 2A,C,D). Some antibodies also altered apoptosis (Figure 2F) and inhibited cell invasion (Figure 2G,H). When we applied some of those antibodies to other cancer cell lines, SFPQ antibody 1A6 inhibited cell proliferation (Figure S2) and invasion in those cancer cells (Figure S3) while knockdown the SFPQ in those cells reduced the antibody inhibition. These data indicate that different SFPQ antibodies affect cancer cells differently. In vivo study, lung cancer cells A549, H648 and H661 were intravenous; (IV) injected into NSG mice, and anti-SFPQ 1A6 or control IgG was applied to the mice six times in intervals of 3 days. There are more cancer cell clusters in the normal, IgG-treated mouse than the SFPQ antibody-treated mouse in haematoxylin and eosin stain, SFPQ IHC analysis and human cell quantification (Figure 2I‒L). Together, these data indicate that SFPQ antibody treatment attenuates the ability of lung cancer cells to grow in vivo. These findings suggest that cell surface SFPQ could be a therapeutic target. We performed an immunoprecipitation proteomics analysis of SFPQ with the cell membrane fraction to identify SFPQ interacting proteins. Proteomic analysis revealed many proteins bound to SFPQ (Table S1). By analysing their possible functions and signal transduction pathways via Ingenuity pathway analysis (https://digitalinsights.qiagen.com/products/qiagen-ipa), these proteins were found to potentially include pathways of signal transduction that impact cell proliferation, apoptosis, metabolism, senescence and migration (Figure 3A,B and Tables S2 and S3). To confirm that these proteins interact with SFPQ, SFPQ antibody immunoprecipitation and Western blotting were performed with antibodies against PPIA, H2AX, S100A4 and VIM in the lung cancer cell membrane fraction (Figure 3C). PPIA, H2AX, S100A4 and VIM bands were present in the SFPQ pull-down material, demonstrating that SFPQ binds to PPIA, H2AX, S100A4 and VIM in the cell membrane. IF double stain also shows SFPQ and S100A4 colocalised in cell membrane (Figure S5). The involvement of S100A4 in cancer cell migration has been reported previously7-9; we then examined the effect of the expression of SFPQ on S100A4 expression and cell invasion in solid cancer cells. SFPQ and S100A4 are higher in lung cancer cell lines (Figure 3D). SFPQ or S100A4 was knocked down with shRNA in lung cancer cells (with scrambled shRNA used as a control), and SFPQ and S100A4 expression levels and SFPQ/S100A4 complex were inhibited (Figure 3E,F). The cell invasion and migration marker MMP2 was reduced in those lung cancer cells with SFPQ or S100A4 knockdown (Figure 3G,H). We also observed if the SFPQ/S100A4 complex exists in other solid cancer cell lines. We found that SFPQ/S100A4 formed a complex in those cancer cells but not in normal bronchial cells (Figure S4). Knockdown SFPQ or S100A4 inhibited cell invasion in breast cancer cells (Figure S5). These indicate that membrane SFPQ/S100A4 affects cell invasion in cancer cells. Taken together, SFPQ is present on the cell surface and affects cell function via interaction with S100A4, PPIA, etc. in lung cancer and other solid cancer cells. Anti-SFPQ antibodies could inhibit cancer cell proliferation and invasion by binding to SFPQ cells. Therefore, cell surface SFPQ may serve as a prognostic marker and therapeutic target for those cancers. Libang Yang and Robert Kratzke conceived, designed and directed the studies with input from Craig A. Henke, Sabine Karam and Scott M. Dehm. Libang Yang and Robert Kratzke wrote the manuscript with assistance from all the authors. Libang Yang, Adam Gilbertsen, Bo Sun, Yingming Li and Blake Jacobson established primary human cell lines, performed Q-PCR, Western blot analysis, performed gain and loss of function experiments, mouse studies and immunohistochemistry. Proteomic sample preparation, mass spectrometry analysis and database searching were performed at the Center for Mass Spectrometry and Proteomics in the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota. Supporting agencies are listed here: https://cbs.umn.edu/cmsp/about. This work was supported by the National Institutes of Health (grant R01 HL125227 to C.A.H.). The authors declare they have no conflicts of interest. This manuscript represents original work, and all sources have been properly cited. Ethical approval was obtained and informed consent was secured where necessary. The data that support the findings of this study are available upon request from the corresponding author. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
BibTeX
@inproceedings{yang2025sfpq,
  author = {Libang Yang and Adam Gilbertsen and Blake A. Jacobson and Robert A. Kratzke and Yingming Li and Bo Sun and Sabine Karam and Scott M. Dehm and Craig A. Henke},
  title = {{SFPQ subcellular mislocalisation entails altered cancer cell function}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1002/ctm2.70431},
}
Figure